On Thursday, Shares of Pfizer Inc. (NYSE:PFE), lost -0.03% to $35.36.
Pfizer declared that the Australian Competition and Consumer Commission (ACCC) has approved the company’s pending acquisition of Hospira, Inc. (HSP) and found no need for remedies.
Completion of the transaction remains subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, governmental and regulatory approvals in certain other jurisdictions and other usual and customary closing conditions.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
Shares of One Horizon Group, Inc. (NASDAQ:OHGI), inclined 21.73% to $1.68, during its last trading session.
One Horizon Group, declared that it has signed a contract to be the exclusive supplier of Voice over IP services to KeyIdea Information Technology Co., Ltd (“KeyIdea”), a renowned manufacturer of satellite equipment in China. KeyIdea will commence operations of their new maritime satellite service in the fourth quarter of 2015 and will supply their crew-calling services exclusively using the Aishuo platform.
One Horizon further expands its subscriber base through the high Revenue Per User (“RPU”) crew-calling distribution channels by providing the newest entrant in the Chinese satellite operator space with a new recurring revenue stream for voice and messaging on top of the traditional equipment sales and satellite airtime rental revenues. KeyIdea will purchase pre-paid calling cards from Aishuo and resell to the crew on-board. Their fleets or crew members will have the availability to top-up online using the App. The calls will be carried through Aishuo’s Public Switched Telephone Network (“PSTN”) in China and billed to the crew on a pay-as-you-go basis.
One Horizon Group, Inc., through its auxiliaries, develops and licenses software solutions to telecommunications operators in Europe, Asia, the Russian Federation, and the United States.
Finally, Amedica Corporation (NASDAQ:AMDA), ended its last trade with -5.02% loss, and closed at $0.53.
Amedica Corporation declared financial results for the second quarter ended June 30, 2015.
Second Quarter 2015 Highlights
- Year-to-date operational cash burn levels reduced by 37% year-over-year.
- Cash and cash equivalents totaled $12.4 million, while net cash used in operating activities during the first half of 2015 reduced by $3.1 million from the preceding year period.
- Two-year performance data from the CASCADE clinical trial will be accessible at the startning of the fourth quarter 2015, with an anticipated final device clearance response from the FDA in late fourth quarter 2015 or early first quarter 2016.
- Signed an original equipment manufacturer (OEM) letter of intent supply agreement with a leading orthopedic device design and manufacturing company.
Amedica Corporation, a commercial-stage biomaterial company, develops, manufactures, and sells a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
